Ab Initio Pharma and Coleus to give podium on fast-track to phase 1 at RDD2022

Join us at RDD2022 to listen to Dr Matthew Read (Principle, Coleus LLC) and Dr Paul Young (CEO, Ab Initio Pharma PTY Ltd) give a podium on the process of taking anew chemical entity from bench to first in human studies. Hear about how the team fast tracked FIH through clever formulation design, robust pre-clinical studies and a structured approach to dose escalation studies. Matthew and Paul will be presenting on May 4th at 230pm in Orlando, Florida. See you there!